This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
RDYPositive Net Change RIGLPositive Net Change BPMCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
5 High Earnings Yield Value Stocks to Buy Amid Market Volatility
by Rimmi Singhi
Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG.
NRGPositive Net Change DANPositive Net Change NUSPositive Net Change PAHCPositive Net Change HRMYPositive Net Change
auto-tires-trucks biotechs consumer-staples energy medical retail
What's in the Cards for Viatris Stock This Q4 Earnings?
by Zacks Equity Research
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
PCRXPositive Net Change VKTXPositive Net Change MIRMPositive Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
ABTPositive Net Change AMGNPositive Net Change MDTPositive Net Change SYKPositive Net Change DXCMNegative Net Change ABBVNegative Net Change
artificial-intelligence biotechnology biotechs medical medical-devices oncology-screening pharmaceuticals
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
PCRXPositive Net Change ARGXNegative Net Change
biotechs earnings
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
PCRXPositive Net Change ARGXNegative Net Change SAVANo Net Change MIRMPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
RGEN reports decent fourth-quarter results and issues guidance for 2025.
RGENPositive Net Change PCRXPositive Net Change ARGXNegative Net Change
biotechs earnings
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
PCRXPositive Net Change INSMNegative Net Change ARGXNegative Net Change DAWNPositive Net Change
biotechs earnings medical
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
by Zacks Equity Research
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.
PCRXPositive Net Change BHCNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
by Zacks Equity Research
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
TEVANegative Net Change FOLDPositive Net Change PCRXPositive Net Change HRMYPositive Net Change
biotechs earnings
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
by Zacks Equity Research
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
SNYNegative Net Change BMRNPositive Net Change ARGXNegative Net Change DAWNPositive Net Change
biotechs earnings medical
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
by Zacks Equity Research
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
BMRNPositive Net Change FOLDPositive Net Change KRYSPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
PCRXPositive Net Change ADMAPositive Net Change VKTXPositive Net Change MIRMPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
by Zacks Equity Research
MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.
GILDPositive Net Change MRNAPositive Net Change SLDBPositive Net Change SEPNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novavax to Report Q4 Earnings: Here's What You Can Expect
by Zacks Equity Research
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
SNYNegative Net Change NVAXPositive Net Change TGTXPositive Net Change ARGXNegative Net Change
biotechs earnings medical vaccines
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
by Zacks Equity Research
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
RHHBYNegative Net Change JNJPositive Net Change HALOPositive Net Change PCRXPositive Net Change
biotechs earnings
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
by Zacks Equity Research
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
JAZZNegative Net Change PCRXPositive Net Change AXSMPositive Net Change HRMYPositive Net Change
biotechs earnings
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
by Sundeep Ganoria
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs cell-therapy crispr medical messenger-rna pharmaceuticals
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.
GSKNegative Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
by Ekta Bagri
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
BMYNegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
by Ahan Chakraborty
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
JNJPositive Net Change PFEPositive Net Change MRKNegative Net Change RXRXPositive Net Change
biotechnology biotechs earnings-preview medical oncology-screening pharmaceuticals
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
by Ekta Bagri
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.
GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.
BMYNegative Net Change PCRXPositive Net Change MIRMPositive Net Change IMCRPositive Net Change
biotechs